Podcast appearances and mentions of Forest Laboratories

Send us a textDr. Manfred Stapff, MD, PhD is a physician and pharmaceutical industry leader with over 30 years of experience in internal medicine, clinical research, and drug development, who has worked across a range of therapeutic areas including NASH, CV, CNS, respiratory, oncology, GI, anti-infective, and orphan diseases.Dr. Stapff has held senior roles at Merck & Co., Forest Laboratories (now Allergan), and LG Chem (CMO / COO), specializing in clinical development, regulatory affairs, and global medical operations. As Chief Medical Officer at TriNetX, he helped build the worldʼs largest real-world data (RWD) research network. Dr. Stapff's expertise spans clinical trials, drug development, regulatory affairs, quality management, and real-world studies.As the founder of Candid Advisory (https://candid-advisory.com/), Dr. Stapff helps organizations leverage real-world data and AI to improve healthcare decision-making and regulatory strategies. Dr. Stapff's new book, Real-World Evidence Unveiled: Navigating the Maze of Modern Misinformation ( https://www.amazon.com/Real-World-Evidence-Unveiled-Navigating-Misinformation-ebook/dp/B0F6DWR6MY?ref_=ast_author_mpb ), explores how misinformation shapes science, media, and public health and how we can separate fact from fiction.#RealWorldEvidence #ManfredStapff #ClinicalTrials #RegulatoryAffairs #RealWorldData #DrugRepurposing #RWE #ArtificialIntelligence #FakeNews #MediaBias #Misinformation #ProgressPotentialAndPossibilities #IraPastor #Podcast #Podcaster #ViralPodcast #STEM #Innovation #Technology #Science #ResearchSupport the show

Synopsis: In this episode, host Rahul Chaturvedi interviews Sarah Boyce, President & CEO of Avidity Biosciences, as she shares her dynamic journey from big pharma to leading groundbreaking advancements in RNA therapeutics. Sarah delves into overcoming drug delivery challenges, the transformative potential of genetic medicine, and Avidity's mission to redefine rare disease treatments. She also offers candid insights on leadership, the importance of cultivating a strong company culture, and balancing personal well-being for long-term success. This episode is essential for those eager to explore the future of biotech and the next wave of medical innovation. Biography: Sarah Boyce joined Avidity as President and Chief Executive Officer and a member of the Board of Directors in October 2019. She has more than 25 years of global leadership experience in both pharmaceutical and biopharmaceutical companies. Sarah's tenure at Avidity has been marked by transformative leadership, starting with the company's successful Series C funding round and IPO. She continues to drive the company's evolution from a research and development entity to a biopharmaceutical company through the advancement of three therapies into clinical development and the expansion of the broad utility of the company's proprietary RNA technology. Prior to joining Avidity, Sarah held the position of president and a member of the board of directors of Akcea Therapeutics. She previously held executive roles in business development and global operations for leading life sciences companies including Ionis Pharmaceuticals, Forest Laboratories, Alexion Pharmaceuticals, Novartis Oncology and Roche. Sarah was named a Healthcare Technology Report Top 25 Biotech CEO in 2022 and has been named one of Fiercest Women in Life Sciences. Sarah currently serves as a member of the board of directors at OmniAb, Inc., Contineum Therapeutics, Inc., and Abcuro, Inc. Sarah holds a BSc (Hons) degree in microbiology from the University of Manchester, England.

Joining us for this episode was Mr. Michael Tutera, the Vice President of Market Access at Nalu Medical. Michael came to the show today with almost 25 years of experience across the Medical Device, Biopharma & Pharma sectors. Michael got his start in the industry by way of Sales and over the years has continued to take on progressive amounts of responsibility in Sales leadership and then of course both Reimbursement & Market Access leadership. He's worked for companies like Forest Laboratories which many of you now know it as Allergan, Mallinckrodt Pharmaceuticals, Intersect ENT which is now part of Medtronic, and of course now now, Nalu Medical.For those unfamiliar with Nalu, it has been repeatedly recognized for its revolutionary technology & innovation including being named as one of the top 100 new products in the world by R&D Magazine. The company was also the gold winner of the 2021 Medical Design Excellence Award and winner of MedTech Visionaries Award for Best MedTech Company & Best Medical Device in the field of neurology. The Nalu Neurostimulation System gives patients more options for managing intractable, chronic pain. Some of the highlights we covered:-How Mike's upbringing shaped the early beginnings of his career-Mike's take on high performance, especially in Market Access -Why some make it to the top of their pyramid & others don't-Toughest challenges in 2024 for Med-Device organizations to achieve market access -How Mike handles stress as a leader with many varying personal & professional responsiblities...and so much more!

Episode Guest: Cynthia R. Green, Ph.D., leading expert in the field of brain health, author, clinical psychologist and founding director of the Memory Enhancement Program at the Mount Sinai Medical CenterEpisode Description: What do advances in neuroscience, increased worldwide longevity, and the obsession with agelessness of the baby boomers have in common? They are all factors in the emerging Brain Age, a time of unprecedented knowledge about the brain, cognition and cognitive wellness. Join Dr. Green to learn more about the revolutionary new science of cognitive health, including what the science really shows about interventions such as brain games and exercise and their impact on brain wellness, and how we can each begin to customize our own path to improved brain vitality. Leave with 9 practical steps you can begin immediately take action to boost your personal brain vitality.In this episode, you'll discover:What it means to be brain healthyHow to achieve better brain healthWhether or not the new brain fitness software programs really workAbout Cynthia R. Green:Cynthia R. Green, Ph.D., is a leading expert in the field of brain health, clinical psychologist and founding director of the Memory Enhancement Program at the Mount Sinai Medical Center, where she is currently an assistant clinical professor of Psychiatry. Dr. Green is the president of Memory Arts LLC and CEO of TBH Brands, the parent company of Total Brain Health, which offers training, products and services to improve memory and brain fitness. Core products of Total Brain Health include the Total Brain Health Toolkits line, a series of "programs in a box" designed for use in active aging, fitness and healthcare settings.Dr. Green is the author of 5 books on brain health, both on her own and in collaboration with major brands such as Prevention and National Geographic. Her collaboration with National Geographic, Your Best Brain Ever, was named a "2013 Top Guide to Life After 50" by the Wall Street Journal. In addition, Dr. Green frequently serves as a consultant to companies on memory and brain fitness (Forest Laboratories, United Healthcare, Lifecare, Marbles) and is a highly regarded keynote speaker for organizational, corporate and association events.Originally from North Carolina, Dr. Green lives with her family in Northern New Jersey. Get in touch with Cynthia R. Green:Visit Cynthia's website: https://totalbrainhealth.com/ Buy Cynthia's Book: https://revolutionizeretirement.com/totalmemory Download Cynthia's Handout: https://revolutionizeretirement.com/green Grab our free guide, 10 Key Issues to Consider as You Explore Your Retirement Transition, at https://10keyretirementissues.com/ 

Unlike many CFOs who tell us that their finance career paths did not intersect with the investor relations (IR) function until shortly before their arrival in the CFO office, Chuck Triano relates that his actually began inside the IR function. In fact, most of the experiences that he credits with shaping his finance leadership portfolio were gleaned during a multi-chapter IR leadership career. Still, Triano's expansive IR resume is not unusual among life sciences CFOs, who say that high-calorie IR/communication skills have long distinguished the sector's finance leadership.    For Triano, whose resume includes a 13-year IR leadership tour with Pfizer and 8 years with Forest Laboratories, the IR path provided an uncompromising view of CFO leadership—one that other members of the finance rank-and-file are unlikely to experience. According to Triano, it's not unusual for IR executives to find themselves seated alongside their CFOs and at times actively assisting the finance leader as he or she seeks to achieve a discerning and influential narrative about the business. Along the way, Triano recalls, his powers of narrative storytelling were put to the test nowhere more than at Pfizer, where at one point he became responsible for “putting down on paper” the company's 6- to 7-year plan. Providing investors with an extended view into the future can be a delicate task, but inside the world of pharmaceuticals—where drug patent expirations loom large—providing an over-the-horizon look for investors can be especially hazardous, admits Triano. Still, Triano realized that there was no turning back.   “We had to make the long-term picture clearer, so we needed to talk about these things and get out in front of them,” reports Triano, who notes that the experience became liberating for the business in a way. Looking back at the task of helping to create Pfizer's long-term outlook, Triano says: “I began by thinking, ‘How do we weave a story out of this?,'” –Jack Sweeney

Suicide rates for our youth and young adults have been climbing since 2001. The reasons for this trend is complex but experts suggest it is a perfect storm of historical events, easy access to distressing information, an unhealthy screen time to outside and social time ratio, and compromised sleep, among other things. The good news is, young people are extraordinary. They have lower mental health bias, they have a desire to help others, and they will change the word. In this episode I speak with John MacPhee, Executive Director for The Jed Foundation about his thoughts on best practices for engaging young people and schools in the work of suicide prevention and mental health promotion.John MacPheeAbout John MacPheeJohn MacPhee brings 30 years of leadership and management experience from the business and not-for-profit settings to his role at the JED Foundation. Passionate about supporting young adults in their transition to adulthood, John advises several organizations including the S. Jay Levy Fellowship for Future Leaders at City College, Trek Medics, Crisis Text Line, the Health Policy and Management Department at the Mailman School of Public Health, and HIV Hero. Earlier in his career, he served in executive positions for Par Pharmaceutical, Inc. and Forest Laboratories, where he oversaw functions such as business development, alliance management, clinical development, regulatory affairs, sales and marketing. John continues to contribute to the development of novel medications for disorders such as Parkinson's disease through board roles with Adamas Pharmaceuticals and Blackthorn Therapeutics. In 2016, John received The Allan Rosenfield Alumni Award for Excellence in the field of public health from the Joseph L. Mailman School of Public Health at Columbia University. He earned a BA from Columbia College, an MBA from New York University and an MPH from Columbia University.About The Jed FoundationThe Jed Foundation is a 501c3 organization that believes in a comprehensive, public health approach to promoting mental health and preventing suicide. JED's programs are grounded in our Comprehensive Approach to Mental Health Promotion and Suicide Prevention for Colleges and Universities and for High Schools. These evidence-based models can be used to assess efforts currently being made in schools, identifying existing strengths and areas for improvement.The programs and resources recommended through the JED Higher Education and JED High School programs have been developed with an equitable implementation lens that ensures that the needs of students who are potentially marginalized and/or underserved due to societal and structural inequities and school-specific community demographics are considered deliberately and intentionally. For more information go to https://www.sallyspencerthomas.com/hope-illuminated-podcast/97

Dr. Angelos Stergiou, President and CEO of SELLAS Life Sciences Group, a late-stage clinical biopharmaceutical company discusses their Phase 3 lead asset, Galinpepimut-S (GPS) a novel immunotherapy that helps to prolong overall survival for cancer patients who are in remission as a monotherapy. He talks about the various indications that GPS targets and the company's focus on the Wilms Tumor 1 (WT1) antigen and why they are the most advanced company working on this in the space. Dr. Angelos M. Stergiou is the founder, President and Chief Executive Officer of SELLAS Life Sciences Group, Inc. Prior to founding SELLAS in 2012, Dr. Stergiou co-founded Genesis Life Sciences, Ltd. (now Genesis Research), a boutique health economics and pricing-reimbursement and health access company, where he served as President and Chief Operating Officer from 2009 to 2011. From 2002 to 2009, Dr. Stergiou held international positions of increasing responsibility in pharmaceutical and biotechnology companies, including PAION AG, Accentia Biopharmaceuticals, BioVest International, Analytica International and Anavex Life Sciences. During this time, Dr. Stergiou held roles ranging from Head of Clinical Research and Vice President of Product Development, Chief Medical Officer and Chief Operations Officer with responsibility for medical affairs, clinical research and development, pharmacovigilance, clinical operations, project management, regulatory affairs, biostatistics and chemistry, manufacturing and controls (CMC). Dr. Stergiou has led and overseen research endeavors in all phases of clinical development across many indications, including CNS, cardiovascular, oncology, respiratory and autoimmune diseases, and has a broad understanding of all aspects of clinical development and medical affairs. He has designed and implemented research projects in the United States, Canada, Australia, Japan and Europe. Dr. Stergiou was a member of the joint steering and oversight committee of PAION AG with Forest Laboratories, Inc. He also led the Phase 3 development of a therapeutic cancer vaccine, BiovaxID, into completion which was presented at the American Society of Clinical Oncology plenary session in 2009 and also holds a patent on the technology. Dr. Stergiou holds a Doctor of Medicine from the U.S. American Institute of Medicine and a Doctor of Science (honoris causa) degree from Kentucky Wesleyan College, and received his Bachelor of Sciences degree from Kentucky Wesleyan College with a major in Pre-Medicine, Biology and Chemistry. Dr. Stergiou is a member of the Board of Trustees at Kentucky Wesleyan College, a Fellow of the Royal Society of Medicine (UK – ID:00707077), an active member of the World Medical Association, a member of the American Academy of Physicians in Clinical Research, a member of the Association of Clinical Research Professionals, and a member of the New York Academy of Sciences. #SELLAS #Cancer #Survival

An exposé of the corruption of medicine by the pharmaceutical industry at every level, from exploiting the vulnerable destitute for drug testing, through manipulation of research data, to disease mongering and promoting drugs that do more harm than good. Authors, Professor Jon Jureidini and Dr Leemon McHenry, made critical contributions to exposing the scientific misconduct in two infamous trials of antidepressants. Ghostwritten publications of these trials were highly influential in prescriptions of paroxetine (Paxil) and citalopram (Celexa) in paediatric and adolescent depression, yet both trials (Glaxo Smith Kline's paroxetine study 329 and Forest Laboratories' citalopram study CIT-MD-18) seriously misrepresented the efficacy and safety data. The Illusion of Evidence-Based Medicine: Exposing the Crisis of Credibility in Clinical Research (Wakefield Press, 2020) provides a detailed account of these studies and argues that medicine desperately needs to re-evaluate its relationship with the pharmaceutical industry. Without a basis for independent evaluation of the results of randomised, placebo-controlled clinical trials, there can be no confidence in evidence-based medicine. Science demands rigorous, critical examination and especially severe testing of hypotheses to function properly, but this is exactly what is lacking in academic medicine. Learn more about your ad choices. Visit megaphone.fm/adchoices Support our show by becoming a premium member! https://newbooksnetwork.supportingcast.fm/neuroscience

An exposé of the corruption of medicine by the pharmaceutical industry at every level, from exploiting the vulnerable destitute for drug testing, through manipulation of research data, to disease mongering and promoting drugs that do more harm than good. Authors, Professor Jon Jureidini and Dr Leemon McHenry, made critical contributions to exposing the scientific misconduct in two infamous trials of antidepressants. Ghostwritten publications of these trials were highly influential in prescriptions of paroxetine (Paxil) and citalopram (Celexa) in paediatric and adolescent depression, yet both trials (Glaxo Smith Kline's paroxetine study 329 and Forest Laboratories' citalopram study CIT-MD-18) seriously misrepresented the efficacy and safety data. The Illusion of Evidence-Based Medicine: Exposing the Crisis of Credibility in Clinical Research (Wakefield Press, 2020) provides a detailed account of these studies and argues that medicine desperately needs to re-evaluate its relationship with the pharmaceutical industry. Without a basis for independent evaluation of the results of randomised, placebo-controlled clinical trials, there can be no confidence in evidence-based medicine. Science demands rigorous, critical examination and especially severe testing of hypotheses to function properly, but this is exactly what is lacking in academic medicine. Learn more about your ad choices. Visit megaphone.fm/adchoices Support our show by becoming a premium member! https://newbooksnetwork.supportingcast.fm

An exposé of the corruption of medicine by the pharmaceutical industry at every level, from exploiting the vulnerable destitute for drug testing, through manipulation of research data, to disease mongering and promoting drugs that do more harm than good. Authors, Professor Jon Jureidini and Dr Leemon McHenry, made critical contributions to exposing the scientific misconduct in two infamous trials of antidepressants. Ghostwritten publications of these trials were highly influential in prescriptions of paroxetine (Paxil) and citalopram (Celexa) in paediatric and adolescent depression, yet both trials (Glaxo Smith Kline's paroxetine study 329 and Forest Laboratories' citalopram study CIT-MD-18) seriously misrepresented the efficacy and safety data. The Illusion of Evidence-Based Medicine: Exposing the Crisis of Credibility in Clinical Research (Wakefield Press, 2020) provides a detailed account of these studies and argues that medicine desperately needs to re-evaluate its relationship with the pharmaceutical industry. Without a basis for independent evaluation of the results of randomised, placebo-controlled clinical trials, there can be no confidence in evidence-based medicine. Science demands rigorous, critical examination and especially severe testing of hypotheses to function properly, but this is exactly what is lacking in academic medicine. Learn more about your ad choices. Visit megaphone.fm/adchoices Support our show by becoming a premium member! https://newbooksnetwork.supportingcast.fm/psychology

An exposé of the corruption of medicine by the pharmaceutical industry at every level, from exploiting the vulnerable destitute for drug testing, through manipulation of research data, to disease mongering and promoting drugs that do more harm than good. Authors, Professor Jon Jureidini and Dr Leemon McHenry, made critical contributions to exposing the scientific misconduct in two infamous trials of antidepressants. Ghostwritten publications of these trials were highly influential in prescriptions of paroxetine (Paxil) and citalopram (Celexa) in paediatric and adolescent depression, yet both trials (Glaxo Smith Kline's paroxetine study 329 and Forest Laboratories' citalopram study CIT-MD-18) seriously misrepresented the efficacy and safety data. The Illusion of Evidence-Based Medicine: Exposing the Crisis of Credibility in Clinical Research (Wakefield Press, 2020) provides a detailed account of these studies and argues that medicine desperately needs to re-evaluate its relationship with the pharmaceutical industry. Without a basis for independent evaluation of the results of randomised, placebo-controlled clinical trials, there can be no confidence in evidence-based medicine. Science demands rigorous, critical examination and especially severe testing of hypotheses to function properly, but this is exactly what is lacking in academic medicine. Learn more about your ad choices. Visit megaphone.fm/adchoices Support our show by becoming a premium member! https://newbooksnetwork.supportingcast.fm/medicine

An exposé of the corruption of medicine by the pharmaceutical industry at every level, from exploiting the vulnerable destitute for drug testing, through manipulation of research data, to disease mongering and promoting drugs that do more harm than good. Authors, Professor Jon Jureidini and Dr Leemon McHenry, made critical contributions to exposing the scientific misconduct in two infamous trials of antidepressants. Ghostwritten publications of these trials were highly influential in prescriptions of paroxetine (Paxil) and citalopram (Celexa) in paediatric and adolescent depression, yet both trials (Glaxo Smith Kline's paroxetine study 329 and Forest Laboratories' citalopram study CIT-MD-18) seriously misrepresented the efficacy and safety data. The Illusion of Evidence-Based Medicine: Exposing the Crisis of Credibility in Clinical Research (Wakefield Press, 2020) provides a detailed account of these studies and argues that medicine desperately needs to re-evaluate its relationship with the pharmaceutical industry. Without a basis for independent evaluation of the results of randomised, placebo-controlled clinical trials, there can be no confidence in evidence-based medicine. Science demands rigorous, critical examination and especially severe testing of hypotheses to function properly, but this is exactly what is lacking in academic medicine. Learn more about your ad choices. Visit megaphone.fm/adchoices Support our show by becoming a premium member! https://newbooksnetwork.supportingcast.fm

An exposé of the corruption of medicine by the pharmaceutical industry at every level, from exploiting the vulnerable destitute for drug testing, through manipulation of research data, to disease mongering and promoting drugs that do more harm than good. Authors, Professor Jon Jureidini and Dr Leemon McHenry, made critical contributions to exposing the scientific misconduct in two infamous trials of antidepressants. Ghostwritten publications of these trials were highly influential in prescriptions of paroxetine (Paxil) and citalopram (Celexa) in paediatric and adolescent depression, yet both trials (Glaxo Smith Kline's paroxetine study 329 and Forest Laboratories' citalopram study CIT-MD-18) seriously misrepresented the efficacy and safety data. The Illusion of Evidence-Based Medicine: Exposing the Crisis of Credibility in Clinical Research (Wakefield Press, 2020) provides a detailed account of these studies and argues that medicine desperately needs to re-evaluate its relationship with the pharmaceutical industry. Without a basis for independent evaluation of the results of randomised, placebo-controlled clinical trials, there can be no confidence in evidence-based medicine. Science demands rigorous, critical examination and especially severe testing of hypotheses to function properly, but this is exactly what is lacking in academic medicine. Learn more about your ad choices. Visit megaphone.fm/adchoices Support our show by becoming a premium member! https://newbooksnetwork.supportingcast.fm

Today we've got a great interview with the CEO of Vesper Healthcare Acquisition Corp. and former CEO of Allergan, Forest Laboratories, and Bausch + Loam Inc, Brent Saunders, about the vaccine. Then we're discussing Apple's new over-the-ear headphones, Moncler's $1.4 billion purchase of Stone Island Sportswear, the motor chief of Nikola's $32.5 million purchase of land in Utah, streaming's impact on Nielsen TV ratings, As Seen on Social, and more. The biggest award show of the year! The 2020 Group Chat Awards LIVE on Twitch December 14th @ 8PM (PST) - Giveaways, special guests, entrainment and more! Mark your calendars www.twitch.tv/groupchatpod Group Chat University, our debut collegiate merch is here! We collaborated with Melrose Place to bring you the best quality merch we could get our hands on. Orders are open for one week, when it’s gone it’s gone! https://www.themenlohouse.com/store/collection/group-chat  28 Days from Freedom – Group Chat News A great interview with return guest, the CEO of Vesper Healthcare Acquisition Corp., Brent Saunders. They discuss all things related to the COVID-19 vaccine, tech talent living away from Silicon Valley, his take on breaking medical news & MUCH MORE! [3:11] Pete Reads the Ads. [47:52] How our public officials have failed us. [52:21] Apple has balls of steel! [55:52] A tale of two companies: Moncler and Nikola, what is considered a success? [1:06:00] Why you should be fired if you’re an advertiser who follows the Nielson ratings. [1:13:30] As Seen on Social. [1:16:08] Group Chat Shout Outs. [1:23:48] Related Links/Products Mentioned Apple to Sell AirPods Max Over-the-Ear Headphones for $549 Moncler Buys Stone Island Sportswear Brand for $1.4 Billion Nikola Motor Chief Sets Utah Real Estate Record With $32.5 Million Buy Jared Kushner and Ivanka Trump are moving to Indian Creek Island. Meet their neighbors Nielsen Sets Timeline for Big Change in TV Ratings Bill Simmons on the Harden Fiasco, Teams He’s High and Low on, Rookie of the Year Picks, and More NBA Memo Says Coaches Must Wear Masks in Arenas, Team Facilities Amid Pandemic How Ohio State vs. Michigan cancellation impacts Buckeyes' Big Ten championship, CFP hopes in 2020 Logan Paul's Orthopedic Surgeon Vs. Floyd Mayweather – Modern Prescription Connect with Group Chat! Watch The Pod #1 Newsletter In The World For The Gram Tweet With Us Exclusive Facebook Content    

Gwen Olsen spent fifteen years as a sales rep in the pharmaceutical industry working for health care giants including Johnson & Johnson, Syntex Labs, Bristol-Myers Squibb, Abbott Laboratories and Forest Laboratories. In 'Confessions of an Rx Drug Pusher', Gwen Olsen brings together the knowledge of an “insider” trained to sell doctors on the merits of pills; the personal experience of having taken psychiatric medications and seen how they altered her life; and the deep grief of having lost her niece—following her treatment with psychiatric medications—to suicide. This book has both an intellectual and emotional punch that readers will long remember. Gwen Olsen featured in the recent documentary 'Prescription Thugs' . Gwen talks with us about the United States representing 5% of the worlds population yet consuming 75% of the worlds prescription drugs. What to do about it and and taking your power back! Gwen Olsen Confessions of a Rx Drug Pusher Gwen Olsen on Facebook

A powerful interview with Dena Faccio. Dena serves as a VOYA Financial Inc. SVP, covering Compensation, Benefits, HR Resolution and Workforce Analytics and is responsible for the Company’s executive and broad based compensation strategy and long-term incentive plans. Prior to joining Voya Financial, Dena spent a year as the head of compensation for Forest Laboratories, a mid-sized global pharmaceutical company. Dena also spent 12 years in PricewaterhouseCoopers’ Global HR Solutions practice in the Retirement and Compensation consulting practices.

Overview The Stevens Group is pleased to present a new podcast series that salutes the masters of public relations and revels in their observations, insights and advice to PR professionals.  This new series is part of the ongoing partnership between The Stevens Group and CommPRO to bring to PR, digital/interactive and marketing communications agencies the wisdom of those who have reached the top of the PR profession.     About Our Guest Shelley Spector, Co-Founder of The Museum of Public Relations & President, Spector & Associates Named as one of the “most innovative” professionals in the field, Spector has produced award-winning campaigns for some of the world's top corporations, including AT&T, Bayer, ITT Corporation, Forest Laboratories, Harris Corporation, and Philips. Spector co-founded the firm in 1991. Within the first year of operation the firm was awarded the Gold Creativity in Public Relations Award for client Embassy Suites.  Since then, the firm has won more than 50 national awards for a variety of Fortune 100 companies. In June 2018, she was presented with the Phil Dorf award for leadership and mentorship at the PRSA New York Big Apple Awards. Prior to co-founding the firm, Spector worked in financial relations for Hill & Knowlton, RuderFinn and Lobsenz-Stevens. She also served as press director for the American Stock Exchange. In 1997, she co-founded the Museum of Public Relations, the world's first and only museum dedicated to preserving and exhibiting the history of the field. It is a 501(c)(3) educational institution, chartered by the New York State Department of Education. Spector serves as an adjunct professor for the graduate Corporate Communications graduate programs at both Baruch College and NYU. She is a frequent guest speaker at academic, industry and corporate events, talking on subjects ranging from “PR in History” to “The Diversity Imperative,” to “Developing Big Ideas.” She is author of “Public Relations for the Public Good” and co-editor of the upcoming book, “Diverse Voices: Profiles in Leadership,” with the PRSA Foundation. A graduate of the Journalism program at the University of Rhode Island, Spector earned an M.S. in Radio/TV/Film at the Newhouse School, Syracuse University.

“It is important that you start with the big picture” - Dr. Manfred Stapff This is episode Dr. Manfred Stapff, Chief Medical Officer at TriNetX shares with us the use and application of real-world data in clinical trial. Manfred Stapff is a physician and board-certified clinical pharmacologist with an extensive career in clinical and pharmaceutical medicine. He was formerly an Executive Director at Actavis, Forest Laboratories, and Merck and also served as a Medical Officer in the German Air Force. Manfred earned his MD and Ph.D. from the Ludwig Maximilian University of Munich. In this interview, Manfred shares his personal story as a general physician for pilots to an industry professional in clinical trials. Manfred also has exceptional advice for physicians looking to get into clinical research. To wrap up, we talk about his role as a liaison between medical science and clinical operations.   I hope you enjoy this interview with Dr. Manfred Stapff. Listen to it on iTunes.Stream by clicking here.Download as an MP3 by right-clicking here and choosing “save as.” Selected Links from the Episode: Connect with Manfred LinkedIn Lancet Drug Information Association (DIA) Association of Clinical Research Professionals (ACRP) Food and Drug Administration (FDA) Journal of Clinical Hypertension American Heart Association (AHA) New England Journal of Medicine (NJEM) TriNetX Merck Good Clinical Practice ICH Show Notes: About TriNetX [02:15] The changing landscape in protocol design [04:16] How TriNetX is helping scientist and health care organizations [06:57] What types of people are companies like TriNetX hiring [10:54] Transitioning from general physician for pilots to Merck [13:32] Advice for medical school students and graduates interested in clinical research [18:12] Working at CROs - what to expect [23:27] Why patient enrollment is challenging [25:29] Why should sites consider being part of networks such as TriNetX [28:11] How clinical (medical) and industry can be advantageous to you [31:08] Importance of doing the “dirty work” in clinical research [32:46] Importance of doing the “dirty work” in clinical research [32:46] Being open to other people’s opinions [36:30] Dealing with tension between science and clinical operations [28:43] Keeping yourself informed about new clinical treatments and scientific findings [46:41] QUESTION: What was most useful for you in this episode? Leave me a comment below and thanks for listening.

Gwen Olsen spent fifteen years as a sales rep in the pharmaceutical industry working for health care giants including Johnson & Johnson, Syntex Labs, Bristol-Myers Squibb, Abbott Laboratories and Forest Laboratories. In 'Confessions of an Rx Drug Pusher', Gwen Olsen brings together the knowledge of an “insider” trained to sell doctors on the merits of pills; the personal experience of having taken psychiatric medications and seen how they altered her life; and the deep grief of having lost her niece—following her treatment with psychiatric medications—to suicide. This book has both an intellectual and emotional punch that readers will long remember. Gwen Olsen featured in the recent documentary 'Prescription Thugs' . Gwen talks with us about the United States representing 5% of the worlds population yet consuming 75% of the worlds prescription drugs. What to do about it and and taking your power back! Gwen Olsen Confessions of a Rx Drug Pusher Gwen Olsen on Facebook Sound Health Options

Gwen Olsen author of,"Confessions Of An Rx Drug Pusher" visits Perfectly Healthy And Toned Radio. Gwen Olsen spent fifteen years as a sales rep in the pharmaceutical industry working for health care giants including Johnson & Johnson, Syntex Labs, Bristol-Myers Squibb, Abbott Laboratories and Forest Laboratories. As a mental health activist, Gwen has testified before the Food and Drug Administration’s Psycho-pharmacology committee, as well as many legislative committees, and has led rallies and marches in protest against psychiatric abuse. Gwen’s message is a call to action and a plea for each of us to step up and do our part to help create a medical system that serves all and does harm to none!

Gwen Olsen is the author of the award-winning book, Confessions of an Rx Drug Pusher. She is also a contributing author to three books, Drugging Our Children by Dr. Sharna Olfman et al, Doctor of the Futureby Dan Yachter, D.C., and the Maximized Living Makeover Manualby Dr. Ben Lerner et al. Gwen has also published health-related articles in the Well Being Journal, Natural News, and the Health News Digest. Gwen is a passionate health activist, writer, and dynamic speaker who devotes much of her time to mental health and child advocacy. Most recently, she is the founder of the Mental Health Alchemists, and provides one-on-one health coaching services and retreats for people who want to reclaim their mental and physical health without drugs. Gwen volunteered as a Court Appointed Special Advocate (CASA) for the Travis County court system from 1995 to 2000, serving as an advocate for abused and neglected foster children in Texas. A 2007 Human Rights Award recipient, she is sought after internationally as a speaker and media resource, and has testified numerous times before Congress and the FDA. A fifteen-year-veteran pharmaceutical rep from 1985 – 2000, Gwen worked for McNeil Pharmaceutical, Syntex Laboratories, Bristol-Myers Squibb, Abbott Labs and Forest Laboratories. She was a hospital rep and specialist rep for the majority of her career, educating residents in hospital teaching settings and selling prescription drugs to doctors in obstetrics and gynecology, orthopedics, cardiology, neurology, endocrinology and psychiatry. Gwen has a unique industry insider’s perspective of the current U.S. healthcare dilemma, and utilizes both her experience and the insight she received in her extensive sales training with Pharma to illuminate marketing trends and illustrate how current greed and conflicts of interest make the system itself the biggest health risk to American consumers. For over a decade, Gwen has made hundreds of appearances and presentations and has been interviewed and featured on national and international television, radio, on-line and print media, documentary films, etc. She is currently featured in the award-winning documentary,Prescription Thugs. www.GwenOlsen.com

Gwen Olsen is the author of the award-winning book, "Confessions of an Rx Drug Pusher." A fifteen-year-veteran pharmaceutical rep from 1985 – 2000, Gwen worked for McNeil Pharmaceutical, Syntex Laboratories, Bristol-Myers Squibb, Abbott Labs and Forest Laboratories. She was a hospital rep and specialist rep for the majority of her career, educating residents in hospital teaching settings and selling prescription drugs to doctors in obstetrics and gynecology, orthopedics, cardiology, neurology, endocrinology and psychiatry. Gwen has a unique industry insider's perspective of the current U.S. healthcare dilemma, and utilizes both her experience and the insight she received in her extensive sales training with Pharma to illuminate marketing trends and illustrate how current greed and conflicts of interest make the system itself the biggest health risk to American consumers. We first 'met' Gwen in Jeff Hays documentary 'Doctored', we know we will have a zesty conversation !  gwenolsen.com Gwen Olsen's Blog - geat articles  Sound Health Options

Anjani Shah, Ph.D., Conference Director, Cambridge Healthtech Institute, interviews Dr. Nhut Diep of Forest Laboratories on February 19, 2014. Dr. Diep will be speaking during the 7th Annual 'Efficient Process Chemistry' conference taking place May 22-23, 2014 as part of CHI's World Pharma Congress May 21-23 in Boston, MA. Efforts to identify a scalable process for preparing DPP-IV inhibitor compounds (diabetes therapeutic) led to the discovery of several useful transformations, including the asymmetric lithiation-boronation of the Boc-pyrrolidine that provided a single compound; the development of a streamline-telescope coupling reaction and workup which led to a robust crystallization/purification method.

Today in FirstWord:

Today in FirstWord:

Today in FirstWord:

1) Orexin receptor antagonism and 2) Topic of the month: Encephalopathy caused by systemic disease. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Ted Burns interviews Drs. Tom Roth and Joe Herring about their paper on orexin receptor antagonism for treatment of insomnia.Dr. Chafic Karam is reading our e-Pearl of the week about central fourth nerve palsies. In the next part of the podcast Dr. Ted Burns interviews Drs. Steven Lewis and Allison Weathers about drugs that can cause encephalopathy. All participants have disclosures.Dr. Burns serves as Podcast Editor for Neurology®; performs EMG studies in his neuromuscular practice (35% effort); and has received research support for consulting activities with CSL Behring and Alexion Pharmaceuticals.Dr. Roth serves on the scientific advisory boards for Merck, Jazz and Transcept; serves as an editorial board member for Sleep and Sleep Medicine; receives research support from Transcept Pharmaceuticals, Impax Pharmaceuticals, Linguflex LLC and APnes, serves on the speakers' bureau of Purdue Pharma L.P. and is a consultant for Abbott Laboratories, Accadia, Acogolix Inc., Acorda, Actelion Pharmaceuticals Ltd, Addrenex Pharmaceuticals, Inc, Alchemers, Alza Corporation, Ancel, Arena, AstraZeneca, Aventis, AVER, Bayer Schering Pharma, BMS, BTG, Cephalon, Inc., Cypress, Dove, Eisai Inc., Elan Corporation, Eli Lilly and Company, Evotec, Forest Laboratories, Inc., GlaxoSmithKline, Hypnion Inc, Impax Pharmaceuticals, Intec, Intra-Cellular Therapies, Jazz, Johnson & Johnson, King Pharmaceuticals, Lundbeck, Inc., McNeil, MediciNova, Merck, Neurim Pharmaceuticals Ltd, Neurocrine, Neurogen, Novartis, Orexo, Organon Pharmaceuticals, Otsuka Pharmaceuticals, Inc., Prestwick, Proctor & Gamble Pharmaceuticals, Pfizer Inc, Purdue Pharma L.P., Resteva, Roche, Sanofi-aventis, Schoering-Plough Corp., Sepracor Inc., Servier Laboratories, Shire plc, Somaxon Pharmaceuticals, Syrex, Takeda Pharmaceutical Company Limited, TransOral, Yanda, VivoMetrics Inc, Wyeth, Yamanuchi Pharmaceutical, and XenoPort.Dr. Herring is Executive Director, Clinical Neuroscience at Merck; receives research support as an employee at Merck and holds stock options with Merck.Dr. Karam serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Lewis serves as CME Section Co-Editor for Neurology® and as Associate Editor for Continuum: Lifelong Learning in Neurology®; receives royalties for the books: Field Guide to the Neurologic Examination and Neurology for the Non-Neurologist and anticipates receiving royalties for the book: Neurologic Disorders due to Systemic Disease.Dr. Weathers receives honoraria as an AAN speaker.

This Podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Jeff Burns interview Dr. Stephen Salloway about his paper on using bapineuzumab in mild to moderate Alzheimer disease. In the next segment, Dr. Ryan Overman is reading our e-Pearl of the week about the Heidenhain variant of Creutzfeldt Jakob disease. The podcast concludes where Dr. Beau Bruce interviews Dr. Brian Weinshenker for the Lesson of the Week (disease of the month) on triptans. The participants had nothing to disclose except Drs. Burns & Salloway. Dr. Burns serves on the Neurology Podcast Committee.Dr. Salloway serves on scientific advisory boards for Myriad Genetics, Inc, Elan Corporation, Sanofi-aventis, Eisai Inc., and Pfizer; serves on the editorial board of the Journal of Neuropsychiatry and Clinical Neurosciences; receives royalties from American Psychiatric Press Inc and Humana Press; received speaker honoraria from Eisai Inc., Pfizer, Novartis, Forest Laboratories, Inc. and Elan Corporation; serves as a consultant to Merck Serono and Medivation-data safety committee; receives research support from Elan Corporation, Wyeth, Bristol-Myers Squibb, Alzheimers Disease Neuroimaging Initiative, Dominantly Inherited Alzheimers Network, Aging Brain: DTI, Subcortical Ischemia and Behavior and NIH [NIA 1 R03 AGO23916-01A1]; receives funding from The Norman and Rosalie Fain Family Foundation.

This Podcast for the Neurology Journal begins and closes with Dr. John H. Noseworthy, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Erik Ensrud interview Dr. Matthew Menza about his paper on patients with Parkinson disease and depression. In the next segment, Dr. Ryan Overman is reading our e-Pearl of the week about asterixis (part two). The podcast concludes where Dr. Julian Bragg interviews Dr. Steve Buyske for the Lesson of the Week segment. The participants had nothing to disclose except for Dr. Menza. Dr. Menza has received consulting honoraria from NIMH, NINDS, GSK, Kyowa, Lilly Research Laboratories, Pfizer, Sepracor, Takeda, and research support from NINDS, Astra-Zeneca, Bristol-Myers Squibb, Boehringer Ingelheim, Forest Laboratories, GSK, Lilly, Pfizer, Sepracor, Takeda Wyeth and Sanofi-Aventis (where he has also received speaking fees).